Ocular Changes in Patients Using Tirzepatide or Semaglutide
Evaluation of Optic Nerve Head, Retinal Changes, and Choroidal Blood Flow in Patients With Diabetes and Obesity Using Tirzepatide or Semaglutide
This prospective observational study aims to evaluate ocular structural and microvascular changes in adults with obesity who are receiving semaglutide or tirzepatide as part of routine clinical care. Participants with and without type 2 diabetes mellitus will be included.
Participants will undergo ophthalmologic examinations at baseline and during follow-up. Changes in optic nerve head parameters, retinal thickness, retinal and choroidal microvascular parameters, and choroidal thickness will be assessed using optical coherence tomography (OCT), optical coherence tomography angiography (OCT-A), and other routine ophthalmologic examination methods.
The study will compare ocular measurements obtained at baseline and during follow-up to investigate changes associated with semaglutide or tirzepatide treatment over a period of up to 18 months.
Studienübersicht
Status
Bedingungen
Intervention / Behandlung
Detaillierte Beschreibung
This prospective observational cohort study will evaluate ocular structural and microvascular changes in adults with obesity receiving semaglutide or tirzepatide as part of routine clinical care. Participants will include individuals with and without type 2 diabetes mellitus.
The study population will be divided into four observational cohorts according to diabetes status and medication use:
- Participants with obesity and type 2 diabetes receiving semaglutide.
- Participants with obesity and type 2 diabetes receiving tirzepatide.
- Participants with obesity without type 2 diabetes receiving semaglutide.
- Participants with obesity without type 2 diabetes receiving tirzepatide.
Participants will undergo ophthalmologic examinations at baseline and during follow-up for up to 18 months. Assessments will include visual acuity, slit-lamp examination, intraocular pressure measurement, fundus examination, optical coherence tomography (OCT), optical coherence tomography angiography (OCT-A), and enhanced depth imaging optical coherence tomography (EDI-OCT).
The study will evaluate changes in retinal nerve fiber layer thickness, retinal thickness, superficial and deep retinal vessel density, foveal avascular zone area, choriocapillaris flow deficit percentage, and choroidal thickness. Changes in visual acuity and intraocular pressure will also be assessed.
Ocular measurements obtained at baseline and during follow-up will be compared to investigate structural and microvascular changes associated with semaglutide or tirzepatide treatment. Differences between the observational cohorts may also be evaluated.
All medications will be prescribed by the treating physicians as part of routine clinical care. Treatment selection will not be determined by the study protocol, and no experimental ophthalmologic intervention will be performed.
Studientyp
Einschreibung (Geschätzt)
Kontakte und Standorte
Studienorte
-
-
Istanbul
-
Istanbul, Istanbul, Türkei (türkiye), 34093
- Rekrutierung
- Istanbul University, Istanbul Faculty of Medicine
-
Kontakt:
- DERYA BUDAK BEHRAD, MD
- Telefonnummer: +90 545 628 0553
- E-Mail: derya.budakbehrad@istanbul.edu.tr
-
Kontakt:
- ADEM TELLIOGLU, MD
- Telefonnummer: +90 5066107361
-
-
Teilnahmekriterien
Zulassungskriterien
Studienberechtigtes Alter
Akzeptiert gesunde Freiwillige
Studienberechtigte Geschlechter
Probenahmeverfahren
Studienpopulation
Adults with obesity who are receiving semaglutide or tirzepatide as part of routine clinical care will be included. Participants will include individuals with and without type 2 diabetes mellitus. The study population will be evaluated in four observational cohorts according to diabetes status and medication: obesity with diabetes receiving semaglutide, obesity with diabetes receiving tirzepatide, obesity without diabetes receiving semaglutide, and obesity without diabetes receiving tirzepatide.
Beschreibung
Inclusion Criteria:
- Age 18 years or older
- Diagnosis of obesity
- Receiving semaglutide or tirzepatide as part of routine clinical care
- Participants with or without type 2 diabetes mellitus
- Availability for baseline and follow-up ophthalmologic examinations
Exclusion Criteria:
- Age under 18 years
- Not receiving semaglutide or tirzepatide
- Inability to complete the required ophthalmologic examinations or imaging assessments
Studienplan
Wie ist die Studie aufgebaut?
Designdetails
- Beobachtungsmodelle: COHORT
- Zeitperspektiven: PROSPECTIVE
Kohorten und Interventionen
Gruppe / Kohorte |
Intervention / Behandlung |
|---|---|
|
Obesity With Diabetes - Semaglutide
Participants with obesity and diabetes receiving semaglutide as part of routine clinical care. |
Semaglutide is prescribed as part of routine clinical care. Treatment is not assigned by the study protocol. Ocular structural and vascular parameters are evaluated before treatment and during follow-up. |
|
Obesity With Diabetes - Tirzepatide
Participants with obesity and diabetes receiving tirzepatide as part of routine clinical care |
Tirzepatide is prescribed as part of routine clinical care. Treatment is not assigned by the study protocol. Ocular structural and vascular parameters are evaluated before treatment and during follow-up. |
|
Obesity Without Diabetes - Semaglutide
Participants with obesity without diabetes receiving semaglutide as part of routine clinical care |
Semaglutide is prescribed as part of routine clinical care. Treatment is not assigned by the study protocol. Ocular structural and vascular parameters are evaluated before treatment and during follow-up. |
|
Obesity Without Diabetes - Tirzepatide
Participants with obesity without diabetes receiving tirzepatide as part of routine clinical care |
Tirzepatide is prescribed as part of routine clinical care. Treatment is not assigned by the study protocol. Ocular structural and vascular parameters are evaluated before treatment and during follow-up. |
Was misst die Studie?
Primäre Ergebnismessungen
Ergebnis Maßnahme |
Maßnahmenbeschreibung |
Zeitfenster |
|---|---|---|
|
Change in Retinal Nerve Fiber Layer Thickness
Zeitfenster: Baseline to up to 18 months
|
Change in retinal nerve fiber layer thickness from baseline during follow-up, assessed using optical coherence tomography (OCT). |
Baseline to up to 18 months
|
|
Change in Retinal Thickness
Zeitfenster: Baseline to up to 18 months
|
Change in retinal thickness from baseline during follow-up, assessed using optical coherence tomography (OCT). |
Baseline to up to 18 months
|
|
Change in Superficial Retinal Vessel Density
Zeitfenster: Baseline to 18 months
|
Change in superficial retinal capillary vessel density from baseline to follow-up, assessed using optical coherence tomography angiography (OCT-A) and expressed as a percentage (%). |
Baseline to 18 months
|
|
Change in Deep Retinal Vessel Density
Zeitfenster: Baseline to 18 months
|
Change in deep retinal capillary vessel density from baseline to follow-up, assessed using optical coherence tomography angiography (OCT-A) and expressed as a percentage (%). |
Baseline to 18 months
|
|
Change in Foveal Avascular Zone Area
Zeitfenster: Baseline to 18 months
|
Change in foveal avascular zone (FAZ) area from baseline to follow-up, measured using optical coherence tomography angiography (OCT-A) and expressed in square millimeters (mm²). |
Baseline to 18 months
|
|
Change in Choriocapillaris Flow Deficit Percentage
Zeitfenster: Baseline to 18 months
|
Change in choriocapillaris flow deficit percentage from baseline to follow-up, assessed using optical coherence tomography angiography (OCT-A) and expressed as a percentage (%). |
Baseline to 18 months
|
Sekundäre Ergebnismessungen
Ergebnis Maßnahme |
Maßnahmenbeschreibung |
Zeitfenster |
|---|---|---|
|
Change in Visual Acuity
Zeitfenster: Baseline to up to 18 months
|
Change in visual acuity from baseline during follow-up |
Baseline to up to 18 months
|
|
Change in Intraocular Pressure
Zeitfenster: Baseline to up to 18 months
|
Change in intraocular pressure from baseline during follow-up, measured in mmHg during routine ophthalmologic examination. |
Baseline to up to 18 months
|
Mitarbeiter und Ermittler
Sponsor
Studienaufzeichnungsdaten
Haupttermine studieren
Studienbeginn (Tatsächlich)
Primärer Abschluss (Geschätzt)
Studienabschluss (Geschätzt)
Studienanmeldedaten
Zuerst eingereicht
Zuerst eingereicht, das die QC-Kriterien erfüllt hat
Zuerst gepostet (Tatsächlich)
Studienaufzeichnungsaktualisierungen
Letztes Update gepostet (Tatsächlich)
Letztes eingereichtes Update, das die QC-Kriterien erfüllt
Zuletzt verifiziert
Mehr Informationen
Begriffe im Zusammenhang mit dieser Studie
Zusätzliche relevante MeSH-Bedingungen
- Erkrankungen des endokrinen Systems
- Ernährungsstörungen
- Stoffwechselerkrankungen
- Überernährung
- Körpergewicht
- Störungen des Glukosestoffwechsels
- Diabetes Mellitus
- Übergewicht
- Pathologische Zustände, Anzeichen und Symptome
- Ernährungs- und Stoffwechselerkrankungen
- Anzeichen und Symptome
- Fettleibigkeit
- Diabetes mellitus, Typ 2
- Aminosäuren, Peptide und Proteine
- Proteine
- Glucagon-ähnliches Peptid-1-Rezeptor
- Glucagon-ähnliche Peptidrezeptoren
- Rezeptoren, G-Protein-gekoppelt
- Rezeptoren, Zelloberfläche
- Membranproteine
- Rezeptoren, Magen -Darm -Hormon
- Rezeptoren, Peptid
- Tirzepatid
- Semaglutid
Andere Studien-ID-Nummern
- 2025/2444
Plan für individuelle Teilnehmerdaten (IPD)
Planen Sie, individuelle Teilnehmerdaten (IPD) zu teilen?
Arzneimittel- und Geräteinformationen, Studienunterlagen
Studiert ein von der US-amerikanischen FDA reguliertes Arzneimittelprodukt
Studiert ein von der US-amerikanischen FDA reguliertes Geräteprodukt
Produkt, das in den USA hergestellt und aus den USA exportiert wird
Diese Informationen wurden ohne Änderungen direkt von der Website clinicaltrials.gov abgerufen. Wenn Sie Ihre Studiendaten ändern, entfernen oder aktualisieren möchten, wenden Sie sich bitte an register@clinicaltrials.gov. Sobald eine Änderung auf clinicaltrials.gov implementiert wird, wird diese automatisch auch auf unserer Website aktualisiert .